Effects of NC-1300, a gastric proton pump inhibitor, on healing of acetic acid-induced gastric ulcers in rats

1989 ◽  
Vol 34 (7) ◽  
pp. 1035-1042 ◽  
Author(s):  
Susumu Okabe ◽  
Hiroki Miyake ◽  
Shinichi Yamasaki
Keyword(s):  
Acetic Acid ◽  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Gastric Ulcers ◽  
Gastric Proton Pump

The effect of a new gastric proton pump inhibitor on serotonin-induced gastric mucosal lesions in rats

1988 ◽  
Vol 23 (5) ◽  
pp. 501-505
Author(s):  
Yoshihisa Tsukamoto ◽  
Saburo Nakazawa ◽  
Kose Segawa ◽  
Hidemi Goto ◽  
Akira Fukui ◽  
...  
Keyword(s):  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Gastric Mucosal Lesions ◽  
Gastric Proton Pump ◽  
Mucosal Lesions

Suppression of Helicobacter pylori-induced Angiogenesis by a Gastric Proton Pump Inhibitor

2005 ◽  
Vol 5 (3) ◽  
pp. 191
Author(s):  
Sung Ho Jin ◽  
Hwa Young Lee ◽  
Dong Kyu Kim ◽  
Yong Kwan Cho ◽  
Ki Baik Hahm ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Gastric Proton Pump

scholarly journals Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man.

Gut ◽  
1983 ◽  
Vol 24 (4) ◽  
pp. 270-276 ◽  
Author(s):  
T Lind ◽  
C Cederberg ◽  
G Ekenved ◽  
U Haglund ◽  
L Olbe
Keyword(s):  
Proton Pump Inhibitor ◽  
Acid Secretion ◽  
Proton Pump ◽  
Gastric Proton Pump

scholarly journals Two Cases of Proton Pump Inhibitor (PPI)-resistant Gastric Ulcers Caused by Gastric Empting Disturbance

2005 ◽  
Vol 54 (2/3) ◽  
pp. 69-74
Author(s):  
Yuki NISHINO ◽  
Jun NISHIKAWA ◽  
Masaaki SATAKE ◽  
Toshihiko MATSUMOTO ◽  
Keiko AKASHI ◽  
...  
Keyword(s):  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Gastric Ulcers

Peptic ulcer disease

2020 ◽  
pp. 2849-2861
Author(s):  
Joseph Sung
Keyword(s):  
Peptic Ulcer ◽  
Proton Pump Inhibitor ◽  
Peptic Ulcer Disease ◽  
Proton Pump ◽  
Gastric Ulcers ◽  
High Dose ◽  
Recurrent Bleeding ◽  
Ulcer Disease ◽  
H Pylori ◽  
Line Of Therapy

Helicobacter pylori infection, use of nonsteroidal anti-inflammatory drugs (NSAIDs) including aspirin, and smoking are the most important causes of peptic ulcer disease. Peptic ulcer disease is characterized by a history of waxing and waning symptoms of localized, dull, aching pain in the upper abdomen. Bleeding is the most common complication; free perforation of the stomach or duodenum into the peritoneal cavity is uncommon but serious. The diagnosis of peptic ulcer disease is made by endoscopy, which offers an opportunity for biopsy of gastric ulcers (which may be malignant) and reveals important prognostic indicators in patients with bleeding ulcers. A single daily dose of a proton pump inhibitor gives quick relief of symptoms and effective healing of peptic ulcers in 4 to 6 weeks. The management of patients with upper gastrointestinal haemorrhage requires a multidisciplinary medical and surgical approach. Early risk stratification based on clinical and endoscopic criteria allows delivery of appropriate care, with endoscopic intervention now widely accepted as the first line of therapy. This should be followed by administration of a high dose of an intravenous proton pump inhibitor to further reduce recurrent bleeding. Treatment of H. pylori is a cure for peptic ulcer disease in most patients. This usually requires at least two antimicrobial agents, with the most popular triple therapy combining a proton pump inhibitor with any two of amoxicillin, metronidazole, and clarithromycin for 7 to 14 days. Eradication of H. pylori infection, avoidance of high-dose NSAIDs or aspirin, and the maintenance use of proton pump inhibitors in high-risk individuals are the best ways to prevent recurrence of ulcer and ulcer complications.

Sign in / Sign up

Export Citation Format

Share Document